AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

AIM ImmunoTech (NYSE American: AIM) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026.

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026. CEO Thomas K. Equels will present a corporate overview and business outlook with emphasis on AIM's strategic focus on pancreatic cancer.

Presentation details: Wednesday, February 11, 2026 at 1:40 PM EST; registration and current corporate presentation on Ampligen breakthroughs are available.

Argus Feb 6 session

-7.32% close to close Open Argus

Details

News Market Reaction – AIM

In the Feb 6 session, AIM declined 7.32%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.3% in the session following this news. A negative reaction despite essentially in...

Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite essentially informational webinar news would have been consistent with prior instances where communication-focused updates drew selling pressure. In that scenario, traders might have focused more on dilution overhang from the effective $100 million shelf and recent offerings than on incremental visibility from the presentation. Past divergence around dividends and media outreach suggests sentiment can turn quickly when no new clinical or financial metrics accompany announcements.

Key Figures

Webinar date range: February 10–11, 2026 Presentation date: February 11, 2026 Presentation time: 1:40 PM EST +1 more

Webinar date range

February 10–11, 2026

Corporate Connect Webinar Series virtual conference

Presentation date

February 11, 2026

AIM corporate overview session

Presentation time

1:40 PM EST

Scheduled start of CEO presentation

Presentation month

February 2026

Ampligen pancreatic cancer corporate presentation

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Clinical trial update

   24h Move

   +16.6%

   Phase 2 interim data for Ampligen plus Imfinzi in pancreatic cancer.

2. Jan 27

   Rights offering terms

   24h Move

   +0.0%

   Amended dates and terms for a planned $12.0M rights offering.

3. Jan 23

   Rights offering launch

   24h Move

   -5.2%

   Announcement of rights offering units with preferred stock and warrants.

4. Dec 30

   Stock dividend

   24h Move

   -4.4%

   One-for-1,000 stock dividend and related allocation details.

5. Dec 10

   CEO communication

   24h Move

   -2.7%

   CEO Corner video discussing unmet pancreatic cancer need and Ampligen.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pancreatic cancer

1 terms

pancreatic cancer medical

"will focus on AIM’s strategic emphasis on pancreatic cancer."

Pancreatic cancer is a disease in which cells in the pancreas grow out of control, forming a tumor that disrupts the organ’s role in digestion and blood-sugar regulation; because it often spreads early and is hard to detect, outcomes tend to be poor. For investors, it matters because diagnosis rates, treatment advances, drug approvals, and clinical trial results can strongly affect the value of biotech and healthcare companies—think of a breakthrough therapy as a new part that could fix a failing engine and reshape market expectations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live video webcast on Wednesday, February 11^th at 1:40 PM EST

OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.

As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM’s strategic emphasis on pancreatic cancer.

Details of the presentation are as follows:

Date and Time: Wednesday, February 11, 2026 at 1:40 PM EST
Presenter: Thomas K. Equels, MS JD, Chief Executive Officer
Registration Link: Here

See AIM's current corporate presentation: Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer: Corporate Presentation – February 2026

About Webull Financial

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will AIM ImmunoTech (AIM) present at the Webull Corporate Connect Webinar Series?

AIM will present on Wednesday, February 11, 2026 at 1:40 PM EST. According to AIM, CEO Thomas K. Equels will deliver a corporate overview and business outlook during the virtual event held February 10-11, 2026, hosted by Webull Financial.

Who will present for AIM (AIM) at the February 11, 2026 webinar and what will they cover?

CEO Thomas K. Equels will present a corporate overview and business outlook. According to AIM, the presentation will emphasize the company's strategic focus on pancreatic cancer and reference the current Ampligen corporate presentation from February 2026.

How can investors register to attend AIM ImmunoTech's (AIM) virtual presentation on February 11, 2026?

Investors can register via the event registration link provided for the Webull Corporate Connect Webinar Series. According to AIM, the presentation is part of the virtual February 10-11, 2026 program and registration details are available through the company's event listing.

Will AIM (AIM) provide materials or a corporate presentation during the Webull webinar?

Yes, AIM will reference its current corporate presentation titled 'Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer: Corporate Presentation – February 2026.' According to AIM, investors can review that presentation for background ahead of the CEO's remarks.

Is the AIM ImmunoTech (AIM) presentation at Webull expected to discuss clinical or financial results?

The presentation will provide a corporate overview and business outlook with emphasis on pancreatic cancer strategy. According to AIM, the focus is strategic and programmatic; no specific financial or clinical readouts are listed in the event details.